Table 2.

Summary of TEAEs

	ENZ110	Nplate	Overall
	(N = 39)	(N = 13)	(N = 52)
All TEAEs, n (%) E	26 (66.7) 111	8 (61.5) 18	34 (65.4) 129
p-value for difference in the incidence of AEs between treatment	0.8679
TEAEs related to investigational product, n (%) E
Possible	15 (38.5) 71	5 (38.5) 12	20 (38.5) 83
Probable/Likely	2 (5.1) 3	1 (7.7) 1	3 (5.8) 4
Unlikely	20 (51.3) 37	3 (23.1) 5	23 (44.2) 42
Severity of TEAEs, n (%) E
Mild	21 (53.8) 76	8 (61.5) 16	29 (55.8) 92
Moderate	12 (30.8) 29	1 (7.7) 2	13 (25.0) 31
Severe	6 (15.4) 6	0 (0.0) 0	6 (11.5) 6
Seriousness of TEAEs, n (%) E
Hospitalization or prolongation of hospitalization	4 (10.3) 4	0 (0.0) 0	4 (7.7) 4
Death	1 (2.6) 1	0 (0.0) 0	1 (1.9) 1
TEAEs leading to discontinuation of IMP	3 (7.7) 3	0 (0.0) 0	3 (5.8) 3

E number of events, N number of subjects dosed with each treatment, n number of subjects with adverse event with particular category, % calculated using the number of subjects treated with each treatment as the denominator (n/N)*100, TEAEs treatment-emergent adverse events, ENZ110 biosimilar romiplostim, Nplate innovator romiplostim, IMP investigational medicinal product